Lithium-Associated Hyperparathyroidism Followed by Catatonia

Objective: To familiarize the medical community with the less common adverse effects of lithium on parathyroid function, we present a case of lithium-associated hyperparathyroidism followed by the development of new-onset catatonia in a patient with schizoaffective disorder. Methods: To allow for th...

Full description

Bibliographic Details
Main Authors: Srinagesh Mannekote Thippaiah, MD, Rachel E. Fargason, MD, Jayasudha G. Gude, MD, Shankarapura N. Muralidhara, MD, Badari Birur, MD
Format: Article
Language:English
Published: Elsevier 2021-05-01
Series:AACE Clinical Case Reports
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2376060520311573
id doaj-33f853655014497cbaac4a754d557ae7
record_format Article
spelling doaj-33f853655014497cbaac4a754d557ae72021-05-16T04:24:15ZengElsevierAACE Clinical Case Reports2376-06052021-05-0173189191Lithium-Associated Hyperparathyroidism Followed by CatatoniaSrinagesh Mannekote Thippaiah, MD0Rachel E. Fargason, MD1Jayasudha G. Gude, MD2Shankarapura N. Muralidhara, MD3Badari Birur, MD4Valleywise Behavioral Health- Maryvale, 5102 W Campbell Ave, Phoenix, Arizona; Address correspondence and reprint requests to Dr. Srinagesh Mannekote Thippaiah, Valleywise Behavioral Health-Maryvale, 5102 W Campbell Ave, Phoenix, AZ 85031.Valleywise Behavioral Health- Maryvale, 5102 W Campbell Ave, Phoenix, Arizona; Department of Psychiatry and Behavioral Neurobiology, University of Alabama at Birmingham, Birmingham, AlabamaValleywise Behavioral Health- Maryvale, 5102 W Campbell Ave, Phoenix, Arizona; Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Glen Oaks, New YorkValleywise Behavioral Health- Maryvale, 5102 W Campbell Ave, Phoenix, Arizona; Park Nicollet Child and Family Behavioral Health Center, Saint Louis Park, MinnesotaValleywise Behavioral Health- Maryvale, 5102 W Campbell Ave, Phoenix, Arizona; Department of Psychiatry and Behavioral Neurobiology, University of Alabama at Birmingham, Birmingham, AlabamaObjective: To familiarize the medical community with the less common adverse effects of lithium on parathyroid function, we present a case of lithium-associated hyperparathyroidism followed by the development of new-onset catatonia in a patient with schizoaffective disorder. Methods: To allow for the safe resumption of lithium, the patient received laboratory screening of serum lithium, blood urea nitrogen, serum creatinine, calcium, and thyroid-stimulating hormone levels. The hypercalcemia was evaluated by measuring parathyroid hormone (PTH), ionized calcium, and 25-hydroxy vitamin D levels. Results: A 58-year-old man with longstanding schizoaffective disorder was admitted for worsening psychotic symptoms following noncompliance with his risperidone and lithium regimen. Exploratory laboratory tests (hospital day 5) showed an elevated PTH level of 72 (reference, 15-65) pg/mL, ionized calcium level of 1.4 (reference, 1.03-1.23) mmol/mL, and a serum calcium level of 11.3 (reference, 8.4-10.5) mg/dL. After the discontinuation of lithium (day 6), anergia (day 7), mutism, and posturing (day 10) developed. Worsening catatonic symptoms of negativism and poor oral intake necessitated dehydration management with intravenous isotonic saline (day 24). The hypercalcemia persisted for 6 weeks. Treatment with cinacalcet (day 43) rapidly normalized the serum calcium levels (day 44). The catatonia, depression, and psychosis began resolving when clozapine (day 50) and electroconvulsive therapy (day 59) were initiated. PTH levels did not normalize until day 82. Conclusion: This report describes a case of prolonged hyperparathyroidism and hypercalcemia following treatment with lithium. Catatonia is unusual in patients with lithium-associated hyperparathyroidism but this report suggests that in settings yet to be determined, it is related to hypercalcemia of this syndrome.http://www.sciencedirect.com/science/article/pii/S2376060520311573catatoniahypercalcemiahyperparathyroidismlithium
collection DOAJ
language English
format Article
sources DOAJ
author Srinagesh Mannekote Thippaiah, MD
Rachel E. Fargason, MD
Jayasudha G. Gude, MD
Shankarapura N. Muralidhara, MD
Badari Birur, MD
spellingShingle Srinagesh Mannekote Thippaiah, MD
Rachel E. Fargason, MD
Jayasudha G. Gude, MD
Shankarapura N. Muralidhara, MD
Badari Birur, MD
Lithium-Associated Hyperparathyroidism Followed by Catatonia
AACE Clinical Case Reports
catatonia
hypercalcemia
hyperparathyroidism
lithium
author_facet Srinagesh Mannekote Thippaiah, MD
Rachel E. Fargason, MD
Jayasudha G. Gude, MD
Shankarapura N. Muralidhara, MD
Badari Birur, MD
author_sort Srinagesh Mannekote Thippaiah, MD
title Lithium-Associated Hyperparathyroidism Followed by Catatonia
title_short Lithium-Associated Hyperparathyroidism Followed by Catatonia
title_full Lithium-Associated Hyperparathyroidism Followed by Catatonia
title_fullStr Lithium-Associated Hyperparathyroidism Followed by Catatonia
title_full_unstemmed Lithium-Associated Hyperparathyroidism Followed by Catatonia
title_sort lithium-associated hyperparathyroidism followed by catatonia
publisher Elsevier
series AACE Clinical Case Reports
issn 2376-0605
publishDate 2021-05-01
description Objective: To familiarize the medical community with the less common adverse effects of lithium on parathyroid function, we present a case of lithium-associated hyperparathyroidism followed by the development of new-onset catatonia in a patient with schizoaffective disorder. Methods: To allow for the safe resumption of lithium, the patient received laboratory screening of serum lithium, blood urea nitrogen, serum creatinine, calcium, and thyroid-stimulating hormone levels. The hypercalcemia was evaluated by measuring parathyroid hormone (PTH), ionized calcium, and 25-hydroxy vitamin D levels. Results: A 58-year-old man with longstanding schizoaffective disorder was admitted for worsening psychotic symptoms following noncompliance with his risperidone and lithium regimen. Exploratory laboratory tests (hospital day 5) showed an elevated PTH level of 72 (reference, 15-65) pg/mL, ionized calcium level of 1.4 (reference, 1.03-1.23) mmol/mL, and a serum calcium level of 11.3 (reference, 8.4-10.5) mg/dL. After the discontinuation of lithium (day 6), anergia (day 7), mutism, and posturing (day 10) developed. Worsening catatonic symptoms of negativism and poor oral intake necessitated dehydration management with intravenous isotonic saline (day 24). The hypercalcemia persisted for 6 weeks. Treatment with cinacalcet (day 43) rapidly normalized the serum calcium levels (day 44). The catatonia, depression, and psychosis began resolving when clozapine (day 50) and electroconvulsive therapy (day 59) were initiated. PTH levels did not normalize until day 82. Conclusion: This report describes a case of prolonged hyperparathyroidism and hypercalcemia following treatment with lithium. Catatonia is unusual in patients with lithium-associated hyperparathyroidism but this report suggests that in settings yet to be determined, it is related to hypercalcemia of this syndrome.
topic catatonia
hypercalcemia
hyperparathyroidism
lithium
url http://www.sciencedirect.com/science/article/pii/S2376060520311573
work_keys_str_mv AT srinageshmannekotethippaiahmd lithiumassociatedhyperparathyroidismfollowedbycatatonia
AT rachelefargasonmd lithiumassociatedhyperparathyroidismfollowedbycatatonia
AT jayasudhaggudemd lithiumassociatedhyperparathyroidismfollowedbycatatonia
AT shankarapuranmuralidharamd lithiumassociatedhyperparathyroidismfollowedbycatatonia
AT badaribirurmd lithiumassociatedhyperparathyroidismfollowedbycatatonia
_version_ 1721439896854331392